How to buy Aerie Pharmaceuticals stock | $13.23

Aerie Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Aerie Pharmaceuticals shares (AERI) are listed on the NASDAQ and all prices are listed in US Dollars. Aerie Pharmaceuticals employs 365 staff and has a trailing 12-month revenue of around 0.00.

Aerie Pharmaceuticals stock price (NASDAQ: AERI)

Use our graph to track the performance of AERI stocks over time.

Aerie Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$13.23
52-week range	$9.01 - $21.30
50-day moving average	$13.26
200-day moving average	$15.63
Wall St. target price	$25.45
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.61

Buy Aerie Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Aerie Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aerie Pharmaceuticals price performance over time

Historical closes compared with the close of $13.23 from 2021-10-15

1 week (2021-10-06)	N/A
1 month (2021-09-17)	2.24%
3 months (2021-07-16)	-13.36%
6 months (2021-04-16)	-23.30%

1 year (2020-10-16)	13.66%
2 years (2019-10-17)	-37.74%
3 years (2018-10-17)	60.04
5 years (2016-10-17)	37.19

Aerie Pharmaceuticals financials

Revenue TTM	$94.9 million
Gross profit TTM	$55.5 million
Return on assets TTM	-22.77%
Return on equity TTM	-663.12%
Profit margin	-175.35%
Book value	$0.51
Market capitalisation	$624.9 million

TTM: trailing 12 months

Shorting Aerie Pharmaceuticals shares

There are currently 7.2 million Aerie Pharmaceuticals shares held short by investors – that's known as Aerie Pharmaceuticals's "short interest". This figure is 36% up from 5.3 million last month.

There are a few different ways that this level of interest in shorting Aerie Pharmaceuticals shares can be evaluated.

Aerie Pharmaceuticals's "short interest ratio" (SIR)

Aerie Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aerie Pharmaceuticals shares currently shorted divided by the average quantity of Aerie Pharmaceuticals shares traded daily (recently around 989059.7260274). Aerie Pharmaceuticals's SIR currently stands at 7.3. In other words for every 100,000 Aerie Pharmaceuticals shares traded daily on the market, roughly 7300 shares are currently held short.

However Aerie Pharmaceuticals's short interest can also be evaluated against the total number of Aerie Pharmaceuticals shares, or, against the total number of tradable Aerie Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aerie Pharmaceuticals's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Aerie Pharmaceuticals shares in existence, roughly 150 shares are currently held short) or 0.1658% of the tradable shares (for every 100,000 tradable Aerie Pharmaceuticals shares, roughly 166 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Aerie Pharmaceuticals.

Find out more about how you can short Aerie Pharmaceuticals stock.

Aerie Pharmaceuticals share dividends

We're not expecting Aerie Pharmaceuticals to pay a dividend over the next 12 months.

Aerie Pharmaceuticals share price volatility

Over the last 12 months, Aerie Pharmaceuticals's shares have ranged in value from as little as $9.01 up to $21.3. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerie Pharmaceuticals's is 0.9444. This would suggest that Aerie Pharmaceuticals's shares are less volatile than average (for this exchange).

Aerie Pharmaceuticals overview

Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Frequently asked questions

What percentage of Aerie Pharmaceuticals is owned by insiders or institutions?
Currently 2.498% of Aerie Pharmaceuticals shares are held by insiders and 108.612% by institutions. How many people work for Aerie Pharmaceuticals?
Latest data suggests 365 work at Aerie Pharmaceuticals. When does the fiscal year end for Aerie Pharmaceuticals?
Aerie Pharmaceuticals's fiscal year ends in December. Where is Aerie Pharmaceuticals based?
Aerie Pharmaceuticals's address is: 4301 Emperor Boulevard, Durham, NC, United States, 27703 What is Aerie Pharmaceuticals's ISIN number?
Aerie Pharmaceuticals's international securities identification number is: US00771V1089 What is Aerie Pharmaceuticals's CUSIP number?
Aerie Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 00771V108